Please assess the completion status of the following clinical trial:

Trial Title: Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A depressive episode according to DSM-V criteria in the course of a bipolar disorder~* MADRS score \> 17~* Already on a mood stabilizer and/or antidepressant~* Patient with a normal or controlled thyroid function~* Male or female both using effective methods of contraception during treatment if sexually active.~Exclusion Criteria:~* - Contraindication to IL-101 therapy:~* Hypersensitivity to active substance or excipient;~* Active infection requiring antibiotics therapy;~* Organ failure (e.g., liver, kidney, lung and heart);~* Immunosuppressed patient~* Hepatotoxic, nephrotoxic, myelotoxic or cardiotoxic drugs~* Other chronic diseases~* Signs of active infection requiring treatment~* Previous history of organ transplantation~* Leukocytes \< 4000 / mm3, platelets \< 100 000 / mm3, Hemoglobin \< 10.0 g/dL or 6.2 mmol/L, red cell blood \< 3.5 T/L.~* Anti-TPO or anti-TG or anti-TRACKS positive at inclusion.~* Use of anti-inflammatory medication on a regular basis for a chronic inflammatory/autoimmune Disorder (NSAD, immunosuppressant IV-Ig based treatment);~* Ongoing fever \< 38~* uncontrolled diabetes type I or II;~* Existing cancer or history of cancer in the last 5 years (except skin epidermoid cancer or in-situ cervix cancer);~* Existing or planned pregnancy or lactation;~* Person under legal protection (1121-8 of CSP, Public Health Code~* Pregnant and parturient and Breast feeding women (1121-5 of CSP)~* legally detained person (1121-6 of CSP)~* hospitalisation without consent~* under the age of majority (1121-7of CSP)~* Immediate risk for suicidal behaviour (MADRS-item 10 \>2 or columbia \> 2 for suicide idea);~* Known HIV infection or clinically manifest Acquired Immune Deficiency Syndrome (AIDS), Parkinson's or Alzheimer's disease, or any other serious condition likely to interfere with the conduct of the trial;~* Participation to an interventional study concomitantly or within 30 days prior to this study, except in the cohorts studies aiming at the analysis of immuno-inflammatory biomarkers and/or brain imaging studies.~* Patients thought to be unreliable or incapable of complying with the requirements of the protocol;~* Patient is relative of, or staff directly reporting to the investigator;~* Patient is employee of the sponsor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- active treatment (Type: EXPERIMENTAL): IL-2 (ILT-101) Sub-cutaneous~1 million UI/j
- placebo (Type: PLACEBO_COMPARATOR): placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).

Based on this trial design, predict the completion outcome and termination type (if applicable).